Pfizer Inc

The SPDR S&P 500 Growth ETF (SPYG) has generated a YTD return of 13.3% versus 4.3% from the SPDR S&P 500 Value ETF (SPYV).

As of June 20, 2017, Bristol-Myers Squibb was trading at a forward PE multiple of ~18.0x—compared to the industry average of 16.0x.

In its press release on June 16, 2017, Bristol-Myers Squibb (BMY) announced that it entered into a definitive purchase agreement with SK Biotek.

On June 15, 2017, Eli Lilly announced data from a study that evaluated the safety and efficacy of Taltz in patients with active psoriatic arthritis.

Growth drivers for Pfizer (PFE) include products contributing to operational growth, such as BMP2, Celebrex, Ibrance, Lyrica, and Xeljanz.

Pfizer (PFE) reported a 2% decline in revenues to ~$12.8 billion for 1Q17, as compared to $13.0 billion in 1Q16.

Pfizer’s Innovative Health segment contributes ~58% of PFE’s total revenues and reported an operational growth of 6% to $7.4 billion for 1Q17.

Elanco, Eli Lilly’s Animal Health business, reported growth of 2% to $769.4 million during 1Q17.

Novartis’s (NVS) Innovative Medicines segment contributed ~67% of NVS’s total revenues in 1Q17.

Novartis reported EPS of $1.13 on revenues of $11.54 billion for 1Q17, which represents 2% YoY operational growth in revenues.

In 1Q17, Amgen’s (AMGN) Repatha witnessed quarter-over-quarter growth in sales volume of ~14% and 28% in the US and Europe, respectively.

GlaxoSmithKline (GSK) is focused on strengthening its vaccines business, so it acquired the meningitis and other vaccines business from Novartis (NVS).

Wall Street analysts expect Pfizer’s (PFE) top line to rise 0.6% to ~$13.1 billion in 1Q17. Its earnings per share are expected to be $0.67 in the quarter.

Novartis’s (NVS) Innovative Medicines segment contributed ~66.6% to overall 1Q17 revenue, or $7.7 billion.

Launched in the US in 2Q16, Exelixis’s (EXEL) Cabometyx managed to fetch revenues of $31.2 million and $44.7 million in 3Q16 and 4Q16, respectively.

The Novartis acquisition has improved sales for GSK’s Vaccines business, mainly driven by the sales of meningitis vaccines Bexsero in Europe and Menveo in the US and Europe.

Novartis’s (NVS) Innovative Medicines segment includes products for therapeutic areas such as oncology, cardiometabolic, immunology, and dermatology.

The US healthcare system is unique in the developed world as it lacks a uniform system and, according to Emanuel, had been largely inefficient before Obamacare.

The overall share of revenues for the Essential Health Products business fell marginally to 44.7% of the total revenues for 2016 from 45.2% of the total revenues for 2015.

Currently, an estimated 7,000 patients suffer from pediatric ALL in the US, Europe, Japan, Canada, and Israel.

Eli Lilly (LLY) reported EPS (earnings per share) of $2.58 on revenue of $21.2 billion in 2016, compared to EPS of $2.26 on revenue of $20.0 million in 2015.

Pfizer (PFE) reported an 8% increase in revenues to $52.8 billion for 2016 as compared to $48.9 billion for 2015.

Novartis (NVS) has managed to secure reimbursement in 17 countries in Europe.

In 2017, Novartis (NVS) expects its heart failure drug, Entresto, to earn revenues in excess of $500 million.

Compared to 43% at the end of 2015, Novartis’s (NVS) Entresto managed to attain a preferred formulary position in 66% of commercial plans in the US at the end of 2016.

Novartis (NVS) expects modest prescription growth for its heart failure drug, Entresto, in 1Q17.

GSK’s Vaccines business reported growth of 14% to ~4.6 billion pounds in 2016.

The Gardasil franchise is Merck’s (MRK) leading vaccines franchise.

Novartis’s Innovative Medicines segment, formerly referred to as its Pharmaceuticals segment, consists of products for therapeutic areas including oncology, respiratory, and established medicines.

Merck (MRK) reported a 1% increase in its revenues to $39.8 billion in 2016.

Merck (MRK) reported growth of 1% to $39.8 billion in its 2016 revenues as compared to $39.5 billion in 2015.

Novartis’s valuation has followed the industry’s overall trend over the last five years. Whether the healthcare sector’s valuation rises or falls, Novartis will definitely be affected.

In 2016, AstraZeneca’s (AZN) poly ADP-ribose polymerase (or PARP) inhibitor, Lynparza, managed to report revenues close to $218 million.

Given the strong performance of Opdivo, Bristol-Myers Squibb’s Oncology segment emerged as its largest revenue contributor in 2016. The segment contributed ~35% of BMY’s total revenue.

Johnson & Johnson’s Medical Devices segment contributed nearly 35% to the company’s total revenues.

For 2016, AstraZeneca (AZN) reported revenues of about $5.8 billion for its emerging markets business, which is a YoY (year-over-year) rise of about 6.0%.

AstraZeneca’s (AZN) Respiratory Product sales fell 3% at constant exchange rates to ~$4.8 billion during fiscal 2016.

In 4Q16, Eli Lilly (LLY) reported Basaglar sales of $40 million from Japan and several European markets.

GSK’s Vaccines segment reported a rise of 18.0% to 1.1 billion pounds in 4Q16. The Novartis acquisition has improved sales for the segment.

On January 31, 2017, Novartis was trading at a forward PE multiple of ~15.2x. Based on its last-five-year multiple range, this is neither high nor low.

The overall contribution from NVS’s Innovative Medicines segment was ~67%, reaching $8.3 billion in 4Q16.

The overall contribution of the innovative medicines segment was ~67% at $8,173 million for 3Q16.

On January 13, 2017, Novartis was trading at a forward PE multiple of ~15.1x.

On October 26, 2016, AstraZeneca (AZN) announced that Lynparza managed to demonstrate a superior clinical profile in the Phase 3 SOLO-2 trial.

GlaxoSmithKline’s (GSK) Pharmaceuticals segment fell substantially in 2015 due to its divestment of its oncology business to Novartis (NVS) in March 2015.

GlaxoSmithKline’s (GSK) business is divided into three business segments: Pharmaceuticals, Vaccines, and Consumer Health.

Amgen (AMGN) launched Enbrel in the US in 1998. It became a major success for Amgen in no time and recorded $5.4 billion sales in 2015.

With the loss of patent protection for its flagship drug, Lipitor, Pfizer’s revenue fell to $48.8 billion in 2015, compared to $67 billion in 2010.

Bristol-Myers Squibb’s (BMY) cardiovascular segment consists of key drug Eliquis. This segment contributed nearly 18% of total revenues for 3Q16.

Teva Pharmaceutical’s (TEVA) generic research pipeline is expected to result in more than 30 first-to-file (or FTF) launches in 2016 and 2017.